Neuromuscular Research Center | Phoenix, AZ

Research site

(Unclaimed)

Location

4545 E Shea Boulevard Suite 175, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Golodirsen

Casimersen

Edaravone

WP-0512

Pregabalin

Miglustat

ATB200

Fasudil

AT2221

SRP-4045

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 14 total trials

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting

Inclusion Body Myositis

Drug: ABC008

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Enrolling

Dermatomyositis

Myositis

Biological: EFG PH20 SC

Other: PBO

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Enrolling

Amyotrophic Lateral Sclerosis

Drug: Fasudil (WP-0512)

Study of M5049 in DM and PM Participants (NEPTUNIA)

The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically der...

Enrolling

Dermatomyositis

Polymyositis

Drug: Placebo

Drug: M5049 high dose

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)

The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants w...

Active, not recruiting

Duchenne Muscular Dystrophy

Drug: Placebo

Drug: SRP-4053

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treat...

Enrolling

Pompe Disease (Late-onset)

Biological: Cipaglucosidase Alfa

Drug: Miglustat